Hosted on MSN

Morgan Stanley Upgrades Vir Biotechnology (VIR)

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of ...
Nasdaq

Citizens Capital Markets Upgrades Sana Biotechnology (SANA)

Fintel reports that on March 18, 2025, Citizens Capital Markets upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Market Perform to Market Outperform. As of March 4, 2025, the average ...